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ABSTRACT 
Parkinson's disease (PD) is amongst the most common age-related neurodegenerative disorders. Natural compounds, especially the polyphenols 
have gained great interest as potential therapeutic agents in recent research. Thus, the present study was designed to evaluate the effect of 
polyphenolic extract of Cymbopogon citratus (C. Citratus) leaves in animal models of PD. In the given study PD was induced by administration of 
reserpine (5 mg/kg/day, i.p for 5 consecutive days), haloperidol (1 mg/kg, i.p.), in experimental animals. The symptoms of PD such as tremors, 
akinesia, rigidity and catalepsy were evaluated. Ethanolic extract of Cymbopogon citratus (CC) in doses of 100, 200 & 400mg/kg were 
administered per oral (PO). The L-dopa and carbidopa (30 mg/kg, PO) combination was used as a positive standard drug.  Behavioural studies 
such as locomotor activity were performed. In catalepsy model, there is significant reduction in catalepsy duration in CC (100, 200, 400mg/kg) 
treated group as compared to the haloperidol group. In reserpine model, there is significant decrease of muscular rigidity, tremors, and akinesia 
in groups treated with CC (100, 200, 400mg/kg) dose dependently. Thus, the present study suggests the beneficial role of C. citratus leaves 
polyphenolic extract in treatment of parkinsonian like symptoms. 
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INTRODUCTION 
In Parkinson’s disease (PD) is a neurodegenerative disorder 
characterised by loss of dopaminergic neurons in the pars 
compacta of the substantia nigra (SN) results in 
parkinsonian syndrome1. It includes symptoms like 
bradykinesia, resting tremor, rigidity, and impairment of 
posture and gait2.  Oxidative stress is thought to play an 
important role in dopaminergic neurotoxicity, mitochondrial 
dysfunction and neuroinflammation. Hence, there is a need 
of maintaining balance between oxidative stress and 
antioxidant system is necessary to preserve the structural 
integrity and optimal functions of brain3.  
 Plant extracts and their constituents act as a natural source 
of antioxidants. The antioxidant activity of several plant 
extracts is due to several secondary metabolites especially 
phenolic compounds4.  In recent times, many evidences 
support that the chronic consumption of polyphenols rich 
diet can promotes the healthy aging and prolongs the healthy 
life span by delaying the age-related disorders like PD. There 
are good evidences which suggest potential utility of 
polyphenols in treatment of PD5.  
Cymbopogon citratus (DC) Stapf (Poaceae), commonly known 
as lemongrass, is widely used in traditional medicine. The 
leaves mainly essential oils. Apart from this, leaves also 
constitute some other phytoconstituents including tannins, 
flavonoids, phenols, steroids, saponins, alkaloids etc. It is 
widely used in the food, pharmaceutical, cosmetic and 
perfumery industries for its essential oil. The literature 
survey indicates that C. citratus, possesses variety of 
pharmacological actions6. In addition to the use of volatile oil 
of the plant, its polyphenol rich extracts have been proven to 
have beneficial effects7. Apart from its therapeutic uses, C. 
citratus is also consumed as a tea, added to non-alcoholic 
beverages and baked food, and used as a flavouring and 
preservative in confections and cuisines. The aqueous 
extracts are also used in traditional medicine. Its infusion 
contains high levels of polyphenols, which are known for 
their antioxidant and anti-inflammatory properties8. 
However, in spite of reported antioxidant and 
neuroprotective activities, no major investigative reports 
found showing its role in Parkinson’s disease.  
Haloperidol and reserpine induced muscle rigidity models 
are important models, being comparatively simpler, is used 
extensively for examining potential symptomatic efﬁcacy of 
new drugs in PD9. Thus, the current study envisages 
evaluation of the anti-parkinsonian effect of C. citratus in the 
management of PD. The study suggests that C. citratus leaves 
polyphenolic extract have potent antioxidant activity which 
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may reduce the degeneration of neurons associated with PD 
and reduces PD like symptoms.  
MATERIALS AND METHODS 
Plant material: The fresh leaves C. Citratus leaves were 
procured from verified supplier. The plant was identified 
and authenticated by Dr. Dongarwar, Assistant Professor, 
Department of Botany Rashtrasant Tukadoji Maharaj Nagpur 
University, Nagpur. A voucher specimen was deposited 
(Voucher Specimen No: 10037). 
Animals: Sprague Dawley rats (150-200 g) of either sex 
were used. Animals were housed under standard conditions 
of temperature (24 ± 2°C) and relative humidity (30-70%) 
with a 12:12 hr light: dark cycle. The animals were fed with 
standard pellet diet and water ad libitum. The Institutional 
Animal Ethical Committee approved the (IAEC Protocols no. 
PJLCP/2015/01) 
Preparation of extracts: Shade dried leaves (100 g) were 
powdered and defatted with petroleum ether to remove 
volatile oils and further extracted with ethanol by using 
Soxhlet’s apparatus. The ethanolic extract of C. Citratus 
leaves (CC) was concentrated under vacuum and evaporated 
to dryness and used for further studies.  
Preliminary Phytochemical Studies: The screening for 
presence of phytoconstituents was carried out as per 
standard procedure described10. 
Total phenolic content determination: The total phenolic 
content of CC was determined by using the Folin–Ciocalteu 
assay11. Total phenolic content of BEPIF was expressed as 
mg Gallic Acid Equivalents. (GAE)/100 g dry weight. All 
samples were analysed in triplicate. 
In vitro antioxidant activity (1, 1-diphenyl-2-
picrylhydrazyl assay): DPPH radical scavenging activity of 
each plant extract was determined in terms of hydrogen 
donating or radical scavenging ability using the stable radical 
DPPH. Briefly, 3 ml of extract was added to 1ml of DPPH 
(2,2,diphenyl-1-picrylhydrazyl ) solution (0.2 mM in 
methanol) as the free radical source. The mixture was 
shaken and kept for 30 min. at room temperature. The 
decrease of solution absorbance due to proton donating 
activity of components of each extract was determined at 
517 nm. Lower the absorbance of the reaction mixture 
indicated higher free radical scavenging activity. Ascorbic 
acid was used as reference standard. Percentage inhibition of 
DPPH free radical was calculated using the following 
equation: 
DPPH Scavenged (%) = [(Ac - AE)/Ac] ×100 
Where Ac is the absorbance of the control, and AE is the 
absorbance of the extract or reference standard. The 
antioxidant activity was expressed as IC50. The IC50 value 
was defined as the concentration in μg/ml of the extract that 
inhibits the formation of DPPH radicals by 50% 12.  
Acute Oral Toxicity of the Extract: The mice were divided 
into 5 groups of 10 animals each. The mice were fasted for 
6h and had access to only water ad libitum before 
experimental study. One group received only vehicle 
(distilled water). Other groups received different doses of CC 
at doses of 1000,2000,3000, and 4000mg/kg, respectively. 
All the doses and vehicle were administered orally. The 
animals were observed for 72h for mortality13. 
Experimental Design: Animals were randomly assigned 
into six groups; each group consisted of six animals (n = 6). 
Group I-vehicle. Group II-reserpine (5 mg/kg, i.p., for 5 
consecutive days), or haloperidol (1 mg/kg, i.p.). PD was 
induced by administration of reserpine, haloperidol in 
animals. Group III-CC (100 mg/kg, p.o.). Group IV-CC (200 
mg/kg, p.o.). Group V-CC (400 mg/kg, p.o.). Group VI-L-dopa 
+ carbidopa (30 mg/kg, p.o.) were used for the treatment of 
Parkinson’s symptoms. 
Haloperidol induced catalepsy: Rats were divided into five 
groups of six each. They were pre-treated with vehicle, CC 
(100, 200 and 300 mg/kg, i.p.), and L-DOPA (30 mg/kg, i.p.) 
30 min before haloperidol (1 mg/kg, i.p.). The duration of 
catalepsy was measured at 0, 30, 60, 90, 120, and 150 min 
after haloperidol administration using bar test. Both the 
forepaws of the animals were placed on a wooden bar 
elevated 9 cm above the ground. The cut off time (time for 
which animal was placed on elevated bar) was 300 
seconds14.  
Reserpine-induced Parkinson Disease: For 5 consecutive 
days, animals were treated with reserpine at a dose of 5 
mg/kg, i.p. After 24 h of last treatment animals were tested 
for induction of severity of tremors. The scores were 
assigned as follows: No tremors-0, occasional twitches-1, 
moderate or intermittent twitches-2, continues tremors-3. 
The number of tremors was counted for 5 min. If animals 
were not showing tremors then 0 score was given, if animals 
showed 1 or 2 tremors then 1 score was given, animals 
showed 3 or 5 tremors then 2 score was given and for 6 or 
more tremors, score was given 3. For evaluating akinesia 
animals were holded with the tail and putting the front paws 
on the platform and let the animal to walk while holding. The 
number of steps taken with forelimbs of animal were 
counted for 3 min. The muscular rigidity was determined by 
suspending the animal with forelimbs on middle part of 
horizontal glass rod (0.5 cm diameter) which was fixed at the 
height of 25 cm above the table top and time to fall on the 
bottom surface was measured. The cut-off was kept for 1 
min. The animals were treated with CC (100, 200 and 400 
mg/kg, p.o., respectively), or L-dopa-carbidopa (30 mg/kg, 
p.o.) 60 min before administration of reserpine for 5 
consecutive days15.  
Locomotor Activity: After evaluation of tremors, akinesia, 
and muscular rigidity, locomotor activity was evaluated by 
using actophotometer. The apparatus consists of 
photoelectric cells, which are connected in circuit with a 
counter. When the beam of light falling on the photocell is 
cut off by the animal, a count was recorded for 10 min16. 
Statistical analysis: The statistical analysis was performed 
using Two-way analysis of variance and one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple 
comparison test. Comparisons were made between 
haloperidol or reserpine group and test/standard groups. P-
values <0.05 was considered statistically significant. The 
statistical analysis was done by using Graph pad prism 
version no: 5.0. 
RESULTS 
Qualitative phytochemical screening: The preliminary 
phytochemical screening of CC showed the presence of 
tannins and phenolic compounds. 
Quantitative phytochemical estimation: Total phenolic 
content of CC was found to be 36.90 mg Gallic acid 
equivalent/100 g of dry weight.  
Antioxidant activity: The IC50 value of CC by DPPH free 
radical scavenging method was found to be 16.30 μg/ml. The 
free radical scavenging activity of BEPIF was found to be 
comparable to ascorbic acid. 
Acute oral toxicity: In acute oral toxicity studies, the CC was 
found to be safe at all the doses used and there was no 
mortality found upto the dose of 4000mg/kg. Therefore, 
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400mg/kg was used as the therapeutic dose and made 
variations by taking 100mg/kg as lower dose and 400mg/kg 
as higher dose. 
Haloperidol induced catalepsy 
Antiparkinsonian activity was studied using haloperidol 
induced catalepsy. In the present study, haloperidol 
produced maximum catalepsy after 90 minutes in vehicle 
treated animals. Pre-treatment with CC at different dose 
(100mg/kg, 200 mg/kg and 400 mg/kg, i.p.) showed a 
significant (P < 0.05, P < 0.001, P < 0.001 respectively) 
reduction in the duration of haloperidol induced catalepsy 
(Fig 1). Application of Two-Way ANOVA showed interaction 
between variables like treatment and time. Two way ANOVA 
followed by post hoc Dunnet test showed that, an decrease in 
cataleptic time was significantly [P<0.001, F (5, 
180=1337.19)] reduced by all doses of CC after 30 min. 
   
  
Figure 1. Effect of ethanolic extract of C. Citratus (CC) on catalepsy time in Haloperidol Model.  
Values are represented as mean ± SEM (n=6) Data was analyzed by Two-way ANOVA followed by Bonferroni multiple comparison test. @P<0.001 
Considered as statistically significant as compared with Vehicle group. *P<0.05, **P<0.01***P<0.001 Considered as statistically significant as 
compared with haloperidol group. 
 
3.6 Reserpine Antagonism 
Treatment with reserpine for 5 days produces muscular 
rigidity, tremors, and akinesia in animals. The intensity of 
muscular rigidity, numbers of tremors, and akinesia were 
significantly decreased by CC at 100, 200, and 400 mg/kg (P 
< 0.05, P < 0.001, P < 0.001 respectively) as compared with 
reserpine treated group. L-dopa-carbidopa treated group 
also showed a significant reversal of reserpine induced 
Parkinson’s symptoms (P < 0.001). (see Figure 2, 3, 4) 
 
 
Figure 2. Effect of ethanolic extract of C. Citratus (CC)) on muscular rigidity in Reserpine model. Values are represented as 
mean ± SEM (n=6) Data was analyzed by one-way ANOVA followed by Bonferroni multiple comparison test. @P<0.001 Considered as statistically 
significant as compared with Vehicle group. *P<0.05, **P<0.01***P<0.001 Considered as statistically significant as compared with haloperidol group. 
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Figure 3. Effect of ethanolic extract of C. Citratus (CC) on 
tremors score in Reserpine model. Values are represented 
as mean ± SEM (n=6) Data was analyzed by one-way ANOVA 
followed by Bonferroni multiple comparison test. @P<0.001 
Considered as statistically significant as compared with 
Vehicle group. *P<0.05, **P<0.01***P<0.001 Considered as 
statistically significant as compared with haloperidol group. 
 
Figure 4. Effect of ethanolic extract of C. Citratus (CC) on 
akinesia in Reserpine model. Values are represented as 
mean ± SEM (n=6) Data was analyzed by one-way ANOVA 
followed by Bonferroni multiple comparison test. @P<0.001 
Considered as statistically significant as compared with 
Vehicle group. *P<0.05, **P<0.01***P<0.001 Considered as 
statistically significant as compared with haloperidol group. 
Thus, the results of haloperidol induced catalepsy and 
reserpine induced tremors, rigidity and akinesia, models 
confirmed the antiparkinsonian activity of CC. 
3.7 Locomotor activity 
The locomotor activity was significantly decreased by 
reserpine as compared to the vehicle group. The locomotor 
activity was significantly (P < 0.01) restored by CC at 100, 
200, and 400 mg/kg and L-dopa-carbidopa (Figure 5). 
 
Figure 5. Effect of ethanolic extract of C. Citratus (CC) on 
Locomotor activity. Values are represented as mean ± SEM 
(n=6) Data was analyzed by one-way ANOVA followed by 
Bonferroni multiple comparison test. @P<0.001 Considered as 
statistically significant as compared with Vehicle group. 
*P<0.05,**P<0.01***P<0.001 Considered as statistically 
significant as compared with haloperidol group. 
 
DISCUSSION 
The present study demonstrates anti-Parkinson activity of 
polyphenolic extract of C. Citratus in different animal models 
like haloperidol and reserpine. 
The present study, haloperidol (1 mg/kg) treated animals 
exhibits cataleptic behaviour similar to the symptoms of PD. 
Haloperidol works by antagonizing dopamine D2 and, to a 
lesser extent, D1 receptors in medium spiny neurons that 
comprise the indirect and direct pathways of the motor 
circuit respectively. The resultant block of striatal dopamine 
transmission results in abnormal downstream ﬁring within 
the basal ganglia circuits that is manifest as symptoms of 
muscle rigidity and catalepsy within 60 min of haloperidol 
(0.5– 5 mg·kg-1, i.p.) injection17. Catalepsy is a behavioural 
state in animals such as mice and rats in which they fail to 
correct externally imposed postures which is not directly 
associated with PD. However, catalepsy may be likened to 
the inability of patients to initiate movements and so could 
be considered a worthwhile measure. Haloperidol-induced 
catalepsy is one of the animal models to test the 
extrapyramidal side effects of antipsychotic drugs. The agent, 
increasing dopamine transmission inhibits neuroleptic 
induced catalepsy. Research showed that acute 
administration of haloperidol reduces striatal content of 
dopamine, noradrenaline and 5-HT18. The ethanolic extract 
of c. citratus (100, 200 and 400 mg/kg, p.o.) showed a 
significant reduction in the duration of catalepsy 
demonstrating antiparkinsonian activity. The inhibition of 
catalepsy indicates the ability of the drug to potentiate 
dopaminergic transmission in the striatum. 
Reserpine works by inhibiting the vesicular monoamine 
transporter (VMAT2). This leads to loss of storage capacity 
and hence depletion of brain (and peripheral) monoamines 
including noradrenaline and 5-HT as well as dopamine. It is 
reported that reserpine produces ~85% loss of dopamine in 
the SNpc and >95%dopamine depletion in the striatum 
within 2 hours of injection 19. CC (200 and 400 mg/kg, p.o.) 
and the combination of L-dopa and carbidopa produced a 
significant reduction in these symptoms in rats. C. Citratus 
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was also able to increase the locomotor activity in rats. As 
reserpine induced motor defect was significantly reversed by 
C. Citratus which demonstrates its anti-Parkinson’s activity. 
The above behavioural results suggest that C. Citratus has the 
ability to improve symptoms of Parkinsonism, in part, by the 
restoring the level of dopamine, and by the regulation of the 
antioxidant system. Thus, antioxidant and neuroprotective 
activities may be responsible for antiparkinsonism effect. 
Hence, C. Citratus may be useful in the treatment of PD. The 
above observed beneficial effects of C. Citratus may be 
attributed due to diverse chemical components mainly 
polyphenols. 
CONCLUSION 
C. Citratus significantly reduced the symptoms of PD may be 
due to antioxidant and neuroprotective activities or increase 
in the level of brain dopamine similar to L-dopa and 
carbidopa. Thus, C. Citratus may have therapeutic potential 
in the treatment of PD. 
Further, studies necessitate the estimation of brain 
dopamine level and isolate the individual constituents 
responsible for potential activity. 
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